In light of the tight connection between Alzheimer’s and prion disease pathologies, compounds such as our PAs that target PrP100–120 and are able to modulate the protective posttranslational cleavage of PrPC might have remarkable effects on Aβ oligomer toxicity or neuroprotection, as presumably also the levels of the N1 fragment increase. Here, PRNP is linked to prion disease.